Form 4: Inhibitor Therapeutics Director Samuel P. Sears Jr. Acquires 50,000 Shares of Common Stock

Director Samuel P. Sears Jr. of Inhibitor Therapeutics, Inc. reports acquiring 50,000 shares of common stock on April 1, 2024, as compensation.

Summary

• On April 1, 2024, Samuel P. Sears Jr., a director of Inhibitor Therapeutics, Inc., acquired 50,000 shares of common stock.
• The acquisition was made as compensation under the Issuer's 2014 Equity Incentive Plan.
• Following the transaction, Sears directly owns 1,129,543 shares of Inhibitor Therapeutics, Inc.
• The transaction was reported on May 16, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a standard transaction. The director's acquisition of shares could be interpreted as a positive signal, but it's primarily a compensation-related event.

Positives

• The acquisition of shares by a director could be seen as a positive sign, indicating confidence in the company's future.

Industry Context

This filing is a routine disclosure related to insider transactions and is a standard practice for publicly traded companies.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Inhibitor Therapeutics, Samuel P. Sears Jr., Director, Stock Acquisition, Common Stock, Equity Incentive Plan, INTI